Innate Pharma ended development of its NK cell engager IPH6501 after a Phase 1/2 program for B-cell non-Hodgkin lymphoma, citing strategic pipeline prioritization. The company said the trial has been discontinued as it focuses on higher-value assets. Innate previously planned to enroll up to 184 patients across the U.S., Australia, and France, but the latest update indicates dose escalation work had been completed while overall program direction changed. Innate also reiterated that data from the discontinued study would be presented later this year. CEO Jonathan Dickinson highlighted ongoing emphasis on assets including IPH4502, an ADC in Phase 1, and lacutamab as it prepares for a Phase 3 program in Sézary syndrome, while noting a key catalyst tied to its AstraZeneca-partnered monalizumab Phase 3 effort in non-small cell lung cancer.